Upcoming Webinar on Implementing Value-Based Care Post-Pandemic
An upcoming webinar will focus on the transition to value-based care and how the COVID-19 pandemic has shifted the timeline. [...]
Bernstein Analysts Say Value-Based Pricing System Feasible; ICER Assessments Could Lower Pharma Revenue by 15%
One proposed method that could reduce drug prices is the use of a value-based system. A recent report by Bernstein [...]
Register Today for June 2nd ISPOR Short Course on HEOR and Cost-Effectiveness Analysis
ISPOR will hold a short course on June 2nd and 3rd designed to provide healthcare professionals information regarding new techniques [...]
CMS Postpones Best Drug Price Requirements Until 2022
A new drug price ruling required a drug’s best listed price to include any discounts. These changes were slated to [...]
Bernstein Analyst Considers Impact of ICER Analytics in Lowering Prescription Drug Prices
Analyst Ronny Gal of Bernstein put forth an investor note where he discussed methods that could bring down high prescription [...]
Tufts Medical Center and National Health Council Report New Partnership to Enhance Value Assessments
The National Health Council (NHC) and the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts [...]
Tufts HEOR Certificate Program Taking Applications
The Tufts Graduate School of Biomedical Sciences and Clinical and Translational Science offers a Health Economics and Outcomes Research (HEOR) [...]
ISPOR Discussion on Overcoming Cost Barriers to Deliver Novel Gene Therapies
ISPOR recently held a panel discussion on how high gene therapy price tags may limit patient access. New gene therapies, [...]
Co-Authors Lead Upcoming Webinar on Transitioning to a Value-Based System
Prescription drug prices continue to rise in the United States, leading to an excessive cost burden placed on patients. A [...]
ISPOR Discussion on Value-Based Healthcare
President of Health Platforms at Verily Life Sciences Dr. Vivian Lee shared her thoughts on the shift to value-based healthcare. [...]
Overused Healthcare is Costly and Ineffective
Overdiagnosis and overtreatment in the healthcare field can lead to high patient costs and even cause harm to patients. Unnecessary [...]
Register Today for ISPOR 2021 Summit on Value Assessments
ISPOR will host its ISPOR Summit on June 10th from 10:00 AM to 3:00 PM EDT. The event will focus [...]
ISPOR Panelists Discuss Incorporating the Patient Voice in Prescription Drug Value Assessments
In a recent virtual ISPOR meeting, panelists discussed how to adjust methods such that patient experiences can be better incorporated [...]
Report Suggests Corporate Environmental and Social Goals Should Include ICER Pricing Assessments
Bernstein analysts suggest that companies implementing environment, social, and governance (ESG) actions should consider drug pricing. They might consider incorporating [...]
PhRMA Director Highlights Four Solutions to Lower Healthcare Costs
The COVID-19 pandemic has placed increase strain on the healthcare system. PhRMA Director of Public Affairs Tom Wilbur discusses four [...]
Report on International Healthcare Systems Notes High Costs in United States and Equity Challenges
The Commonwealth Fund has published a report that provides a comprehensive look into healthcare systems around the world. In the [...]
ICER Announces Cloud-Based ICER Analytics Platform
The Institute for Clinical and Economic Review (ICER) has announced the launch of ICER Analytics. The new cloud-based tool is [...]
ISPOR Signal Virtual Event on Value and Pricing Strategies
ISPOR will host its second event in its new Signal series on June 25th, from 11:00 AM to 12:00 PM [...]
Interactive Wednesday Webinar on Effective Medical Communication
Medical communication is becoming increasingly important for payers, pharma, and healthcare professionals. NetworkPharma will host a webinar this week on [...]
JAMA Report on Reducing Prescription Drug Prices Using Legislation, Notes 159% List Price Increase in 11 Years
A new report discusses legislation that could reduce skyrocketing drug prices. Attempts at the state level have put forth unsupported [...]
Insights on Excessive Drug Costs and Using QALYs to Determine Value
Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center and [...]
Federal Agency Proposes Penalties if Pharma Forgoes Clinical Trials
The Medicaid and CHIP Payment and Access Commission has voted to demand pharma companies pay higher Medicaid rebates if they [...]
HEOR Experts Release Recommendations to Spur Volume-to-Value Shift and Improve Healthcare Equity
Researchers at the Leonard Davis Institute of Health Economics at the University of Pennsylvania have released a set of recommendations [...]
HTA Whitepaper Discusses Resulting Value and Economic Benefits
In a whitepaper by researchers at the USC Schaeffer Center and Aspen Institute Advisory Panel, the authors discuss how an [...]
Bundled Payment Healthcare Program Saves Over $16,000 per Procedure and Leads to 75% Lower Readmission Rate
Carrum Health led a bundled payment program, resulting in substantial savings when it comes to the cost of surgical and [...]